The involvement of osteocytes in multiple myeloma (MM)-induced osteoclast (OCL) formation and bone lesions is still unknown. Osteocytes regulate bone remodelling at least partially, as a result of their cell death triggering OCL recruitment. In this study, we found that the number of viable osteocytes was significantly smaller in MM patients than in healthy controls, and negatively correlated with the number of OCLs. Moreover, the MM patients with bone lesions had a significantly smaller number of viable osteocytes than those without, partly because of increased apoptosis. These findings were further confirmed by ultrastructural in vitro analyses of human preosteocyte cells cocultured with MM cells, which showed that MM cells increased preosteocyte death and apoptosis. A micro-array analysis showed that MM cells affect the transcriptional profiles of preosteocytes by upregulating the production of osteoclastogenic cytokines such as interleukin (IL)-11, and increasing their pro-osteoclastogenic properties. Finally, the osteocyte expression of IL-11 was higher in the MM patients with than in those without bone lesions. Our data suggest that MM patients are characterized by a reduced number of viable osteocytes related to the presence of bone lesions, and that this is involved in MM-induced OCL formation. Keywords: multiple myeloma; osteocytes; bone disease; osteoclasts
INTRODUCTION
The presence of osteolytic bone lesions or osteoporosis is the hallmark of multiple myeloma (MM), and leads to bone fragility and fractures in MM patients. The bone lesions are characterized by severely unbalanced and uncoupled bone remodelling in the area of plasma cell infiltration due to increased osteoclast (OCL) formation and activity, and osteoblast (OB) suppression. 1 --3 Local factors produced by MM cells and the bone marrow microenvironment are involved in the MM-induced increase in osteoclastogenesis, and include an imbalance in the receptor activator of nuclear factor kappa-B ligand (RANKL)/osteoprotegerin (OPG) ratio that favours RANKL, 2, 4 and the MM cell production of osteoclastogenic factors such as Chemokine (C --C motif) ligand 3 (CCL3)/macrophage inflammatory proteins (MIP)-1a. 5 --7 OB exhaustion is mainly due to a reduction in OB differentiation and formation, from mesenchymal stem cells and OB progenitors, that is induced by MM cells as a result of cell-to-cell contacts and the release of soluble factors. 3,8 --11 Osteocytes are differentiated cells of osteogenic lineage 12 located in the lacuno-canalicular system of the bone (see the review by Bonewald). 13 There is increasing evidence that they regulate physiological local bone remodelling, 13 --16 partly as a result of the cell death and apoptosis that triggers OCL formation and bone resorption, 15 --19 and partly by secreting sclerostin, a molecule that is specifically produced by osteocytes that inhibits bone formation. 20, 21 Interestingly, an apoptosis-related reduction in osteocyte viability has recently been demonstrated in osteoporotic bone caused by estrogen deficiency 22, 23 or glucorticoid administration, 24, 25 which suggests that osteocytes are involved in OCL recruitment under pathophysiological conditions characterized by increased bone resorption. Furthermore, osteocyte-ablated mice show bone fragility microfractures, osteoblastic dysfunction and trabecular bone loss. 26 As the potential involvement of osteocytes in the bone remodelling alterations associated with MM is largely unknown, we evaluated osteocyte viability in bone biopsy samples obtained from patients with MM or monoclonal gammopathy of undetermined significance (MGUS) and healthy subjects. Osteocyte viability in the MM patients correlated with the number of OCLs and the occurrence of bone lesions, and these in vivo findings were supported by in vitro evidence obtained using a preosteocytic cell line (HOB-01) established from human bone. 27 
SUBJECTS AND METHODS

Histological evaluation of MM patients and controls
The study involved a cohort of 31 MM patients (16 females and 15 males, with a mean age ± s.d. of 73 ± 9 years) at the time of diagnosis (n ¼ 14) or relapse (n ¼ 17), 52% of whom had radiographic evidence of osteolytic lesions involving the pelvis; 10 MGUS patients with a mean age of 71±14 years; and 10 age-and gender-matched controls with a mean age of 68 ± 14 years, who showed no signs of hematological malignancies or metabolic bone diseases such as osteoporosis evaluated by dual-emission X-ray absorptiometry (DEXA) (defined: T score À2.5).
The study was approved by our local Ethics Committee and was carried out in accordance with the principles of the Declaration of Helsinki.
None of the patients with newly diagnosed MM had received bisphosphonates, but all of the patients with relapsing MM and bone lesions had received monthly zoledronic acid for 2 years, although they were not taking it at the time of the study. None of the healthy controls were receiving or had previously taken bisphosphonate therapy, and the female subjects had never undergone estrogen therapy.
Cylindrical iliac biopsies (3 mm in diameter and 10 mm in length) were obtained from the patients and controls, fixed in sodium phosphatebuffered 4% paraformaldehyde, pH 7.4, dehydrated in a graded series of ethanol, and embedded in paraffin using the standard method. The bone samples were longitudinally sectioned by means of a microtome cutting system (Leica S.p.A., Milan, Italy) in order to obtain sections that were 5 mm thick, and then stained with toluidine blue and Gomori's trichrome stain (Polysciences, Inc., Eppelheim, Germany).
Osteocyte viability was evaluated in a total of 500 lacunae per histological section, and two groups of data were collected: (1) the number of viable osteocytes and (2) the number of degenerated or apoptotic osteocytes and empty lacunae. Given the mean size of the biopsies (3 Â 10 mm 2 ), the number of lacunae examined approximately corresponds to the total number of osteocyte lacunae in the sections of the MM patients; in the sections of the MGUS patients and healthy controls that contained more than 500 lacunae, those in excess were randomly excluded from the analysis but had the same viability.
The OCLs and active prismatic OBs in the same histological sections were also counted per section of bone surface (3 Â 10 mm 2 ) on the basis of morphological criteria. The sections were observed and analyzed using a light microscope (Zeiss Axiophot, Jena, Germany) equipped with an image analysis system (a Nikon DS-5Mc camera connected to a personal computer---NIS Elements AR 2.20 Nikon software, Nikon Inc., Melville NY, USA).
In situ end-labelling analysis (terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL)) Sections taken from the same biopsies underwent in situ end-labelling analysis (TUNEL) in order to evaluate the amount of osteocyte apoptosis using the ApopTag peroxidase in situ apoptosis kit (Millipore, Billerica, MA, USA) according to the manufacturer's recommendations.
Reagents
Recombinant human (rh) interleukin (IL)-11, RANKL and M-CSF (macrophage colony-stimulating factor) were obtained from Endogen (Woburn, MA, USA); rhCCL3/MIP-1a was purchased from R&D Systems (Minneapolis, MN, USA); RPMI-1640, D-minimal essential medium and a-minimal essential medium culture media, and glutamine, penicillin, streptomycin and fetal bovine serum were purchased from Invitrogen Life Technologies (Milan, Italy).
Cells and cell culture conditions Cell lines. The human myeloma cell lines (HMCLs) JJN3, RPMI-8226 and the human B-lymphoblastoid cell line IM-9 were purchased from DSMZ (Braunschweig, Germany). The HMCL XG-1 was kindly provided by Martine Amiot (Nantes, France), and KMS12 and KMS27 by Antonino Neri (Milan, Italy). The erythroleukemic cell line K562 was obtained from American Type Culture Collection, and the pre-B acute lymphoblastic leukemia cell line 697 was kindly given by Dr Irma Airoldi (Genoa, Italy). The human preosteocytic cells HOB-01 were established from human bone 27 and kindly provided by Julia Billars (Collegeville, PA, USA).
Cocultures. Sub-confluent HOB-01 human preosteocytes were cocultured with the HMCLs, the leukemic cell lines or freshly purified MM cells, isolated immunomagnetically using anti-CD138 monoclonal antibody (Ab)-coated microbeads (MACS, Miltenyi Biotec, Bergisch-Gladbach, Germany) as previously described, 4 and placed in a transwell insert for 24 --72 h.
Osteocyte viability. Osteoclastogenesis. Peripheral blood mononuclear cells were obtained from healthy donor buffycoats after Ficoll-Hypaque gradient centrifugation (Biochrome AG, Berlin, Germany). The cells were incubated in a-minimal essential medium with 10% fetal bovine serum, RANKL (60 ng/ml) and M-CSF (25 ng/ml) in the presence of rhIL-11 (10 ng/ml), rhCCL3 (0.5 ng/ml), vehicle, CM/a-minimal essential medium at 10% fetal bovine serum (ratio 1:4) from HOB-01 cells cocultured with HMCLs in the presence or absence of neutralizing anti-IL-11 Ab (7.5 mg/ml; R&D Systems) or anti-CCL3 (0.5 mg/ ml; R&D Systems), anti-immunoglobulin G control isotype Ab (3.5 mg/ml; R&D Systems) for 28 days, with the media being replaced every 4 days. OCL formation was assessed by means of cytochemical analysis using the commercial Tartrate Resistant Acid Phosphatase kit (Sigma-Aldrich, Milan, Italy), and the OCLs were scored as multinucleated tartrate resistant acid phosphatase-positive cells (43 nuclei) and counted by light microscopy. OCL activity was evaluated using the pit assay method (Pantec Srl., Turin, Italy).
Enzyme-linked immunosorbent assays (ELISAs)
Aliquots of 48-h CM of HMCLs, HOB-01 cells and cocultures were tested by means of ELISAs of soluble IL-11, MMP-1 (matrix metalloproteinase), CCL3, TNFa (R&D Systems), RANKL and OPG (Pantec Srl). The cytokine levels were normalized to protein levels in the CM as measured by means of a protein assay (BioRad, Hercules, CA, USA).
Gene expression profiling analysis
The transcriptional profiles of HOB-01 cells cocultured in the presence or absence of the HMCL JJN3 were generated in triplicate on GeneChip HG-U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA, USA) using the manufacturer's standard preparation and hybridization protocols. The data were extracted from CEL files and converted to normalized signals using conventional GeneChip Operating Software (GCOS, Affymetrix) 1.1 scaling. The differential expression of the transcripts was tested using DNA Chip analyzer software, with the condition of at least a two fold variation in absolute expression levels between the control and cocultured cells and a difference between the average expression values of 4100, allowing a deviation of o90% of the confidence interval in order to preserve consistency within the two groups. The data discussed in this article have been deposited with the National Center for Biotechnology Information's Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo), and are accessible through GEO Series accession number GSE27372.
Real-time quantitative PCR
Total cell RNA was extracted using the RNeasy mini kit (Qiagen s.r.l., Milan, Italy), and 1 mg of RNA was reverse-transcribed using the MuLV Reverse Transcriptase in accordance with the manufacturer's protocol (Invitrogen). Real-time PCR was performed by adding 2 of the 20 ml of cDNA obtained from 1 mg of RNA to universal master mix primers and TaqMan probes (Applied Biosystems, Applera, Milan, Italy). The TaqMan gene expression assays used were Hs 00233958_m1 (MMP1), Hs01055414_m1 (IL11), Hs00234142_m1 (CCL3), Hs01092186_m1 (RANKL), Hs0800171068_m1 (OPG), Hs01104728_m1 (ABL), Hs99999905_m1 (GAPDH) and 4333766F (B2M).
The comparative C t method was applied to normalize for differences in RNA quality and reverse transcription efficiency, using the endogenous reference genes ABL, GAPDH and B2-microglobulin (B2M). The mRNA was relatively quantified using the DC t method, with DDC t being calculated as the difference between the DC t of a sample and the DC t of the control. The fold change in mRNA expression (n-fold) was calculated as 2
ÀDDCt .
Immunohistochemistry
Briefly, paraffin-embedded sections were deparaffinized and heat-induced antigens were retrieved using 10 mM of citrate buffer (pH 6.0) in an 80 1C bain-marie for 60 min; endogenous peroxidase activity was quenched using 3% hydrogen peroxide for 10 min. The slides were then incubated with the primary antibodies rabbit anti-IL-11 Ab (working dilution, 1:100; Novus Biologicals, CO, USA), anti hRANKL monoclonal Ab (1:25, R&D Systems) or anti-hOPG monoclonal Ab (1:100; R&D Systems) for 60 min at room temperature. Serial sections of 3 mm were stained for sclerostin, without antigen retrieval, using the anti-SOST Ab (1:250; R&D Systems), which was detected by means of a highly sensitive immunohistochemistry detection system (Advance-HRP, Dako Carpinteria, CA, USA) using 3,3-diaminobenzidine as the chromogen substrate. Sections were stained with a 0.3% solution of light green to facilitate the evaluation of osteocytes within the bone trabeculae.
RESULTS
Increased osteocyte death characterizes MM patients, and correlates with the presence of bone lesions
We first histologically analyzed the bone biopsies obtained from iliac crests of 31 patients (mean age ± s.d. 73 ± 9 years; median 75 years; range 52 --86 years), with newly diagnosed (n ¼ 14) or relapsing MM (n ¼ 17), ISS I --III (I ¼ 12, II ¼ 12, III ¼ 7), 61% with type k and 39% with type l. The mean age±s.d. of the patients with (52%) and without (48%) osteolytic bone lesions involving the pelvis was respectively 71 ± 8 and 75 ± 11 years (P ¼ 0.2; NS). The patients' characteristics are summarized in Supplementary  Table S1 . The mean age of the MGUS patients was 71±14 years (median 76; range: 48 --85), and that of the healthy controls (N) was 68 ± 14 years. Histological analysis of the bone biopsies showed that the MM patients had significantly more death osteocytes/empty lacunae ( Figure 1a ) and significant fewer viable osteocytes than the controls but not the MGUS patients (Figure 1b) . In terms of skeletal involvement, the MM patients with osteolytic lesions had significantly more dead osteocytes and empty lacunae ( Figure 1a ) and significantly fewer viable osteocytes (Figure 1b ) than those without osteolytic lesions. Figure 1c shows Gomori's trichrome staining of sections of the iliac crest biopsies obtained from two representative MM patients. The MM patients with bone lesions had significantly more dead osteocytes than the MGUS patients (P ¼ 0.04), whereas there was no significant difference between the MM patients as a whole and the MGUS patients (P ¼ 0.2). Interestingly, there was no significant difference between the newly diagnosed and relapsing MM patients (P ¼ 0.9). However, the number of death osteocytes was higher in MM patients with osteolytic lesions who had received bisphosphonates those who had not, even if the difference did not reach a statistical significance (P ¼ 0.08, NS).
Light microscopy and TUNEL analyses showed that the increased osteocyte death in the MM patients with bone lesions was at least partially due to increased osteocyte apoptosis, as demonstrated by their significantly increased TUNEL reaction (P ¼ 0.05; see Figure 1d , panels i, ii and iii).
The mean number of active prismatic OBs arranged in the laminae of the MM patients (mean number/section ± s.e.: 13±0.97) was significantly lower than that observed in the MGUS patients (40±4; P ¼ 0.05) or the controls (75±8; P ¼ 0.02). The difference between the MGUS patients and controls was not statistically significant (P ¼ 0.26; Figure 2 ). There was no significant relationship between the numbers of OBs and viable osteocytes in the MM patients (Spearman's r: 0.82; P ¼ 0.65).
Relationship between osteocytes and OCLs in MM patients In order to verify the potential relationship between osteocyte viability and OCLs, we counted the number of OCLs attached to the bone per section ( Figure 3 shows the findings in a representative newly diagnosed patient). This was significantly higher in the MM patients than in the healthy subjects (P ¼ 0.041) or MGUS patients (P ¼ 0.048) ( Table 1 ). Moreover, the MM patients with bone lesions had more OCLs than those without, although the difference was not statistically significant (P ¼ 0.18) ( Table 1) . Similarly, the difference in the number of OCLs in relapsed vs newly diagnosed MM patients did not reach statistical significance (P ¼ 0.13). Finally, there was a significant negative correlation between the number of viable osteocytes and the number of OCLs in the MM patients (Spearman's r: À0.33, P ¼ 0.04) (Figure 3 ), thus suggesting a relationship between osteocyte death and osteoclastogenesis in vivo.
MM cells increase osteocyte death in cocultures
As we found that the significant increase in osteocyte death in MM patients correlated with the presence of bone lesions and the number of OCLs, we verified the in vitro effect of MM cells on osteocyte survival using a coculture transwell system, HMCLs and the HOB-01 human preosteocyte cell line. Table S2 ). These included increases in the expression of the pro-osteoclastogenic genes IL11 (probeset 206924_at; FC: 3.09) and MMP1 (probeset 204475_at; FC: 11.83), a metalloproteinase involved in tumoral osteolysis.
The upregulation of IL11 and MMP1 mRNA expression in HOB-01 cells cocultured with JJN3 cells was confirmed by real-time PCR (Figure 5a ) and further explored by means of cocultures with other HMCLs including XG-1, RPMI-8228 and KMS27, all of which induced IL11 and MMP1 mRNA upregulation, with the exception of KMS27 in the case of MMP1 (Figure 5a ). The B-lymphoblastoid cell line IM-9 had a slightly stimulatory effect on IL11 but not on MMP1 mRNA expression (o2-fold), and the non-myeloma cell lines K562 and 697 did not affect either IL11 or MMP1 mRNA expression (Figure 5a ). In line with these findings, the protein levels of IL-11 ( Figure 5b ) and MMP-1 ( Figure 5c ) were significantly upregulated in the CM of HOB-01 cells cocultured with HMCLs, but not in the CM of HOB-01 cells cocultured with IM-9, K562 or 697 (Figures 5b and c) .
The mRNA expression and protein levels of RANKL and CCL3/ MIP-1a (the pro-osteoclastogenic cytokines most involved in MMinduced OCL formation) were also evaluated in cocultures. RANKL and OPG were not expressed by HOB-01 cells, and RANKL levels and the RANKL/OPG ratio were unchanged in the cocultures (data not shown), but we found that CCL3/MIP-1a protein levels were significantly higher in the CM of the cocultures of HOB-01 cells and HMCLs than in those of the HMCLs or HOB-01 cells cultured alone (Figure 5d) . Interestingly, the upregulation of CCL3/MIP-1a was not observed in the CM of HOB-01 cells cocultured with IM-9, K562 or 697. Finally, real-time PCR showed that CCL3/MIP-1a expression was upregulated in the HMCLs but not the HOB-01 cells (Figure 5e ).
Conditioned media of preosteocytes cocultured with HMCLs stimulates OCL formation: the role of IL-11 and CCL3 In line with the increase in pro-osteoclastogenic cytokine levels observed in the cocultures of HMCLs and preosteocytes, the CM of HOB-01 cells cocultured with JJN3 or KMS12 cells significantly increased osteoclastogenesis and OCL activity in comparison with the CM of HOB-01 cells cultured alone (Figure 6a) , and so we investigated the role of the pro-osteoclastogenic cytokines that were upregulated in the cocultures of HOB-01 cells and HMCLs. Interestingly, both CCL3 and IL-11 increased OCL formation, and the pro-osteoclastogenic effect of the CM of the cocultures was Figure 2 . Osteoblastic evaluation in MM and MGUS patients, and healthy subjects. The OBs in the bone sections of MM and MGUS patients, and healthy subjects were identified in the osteoblastic laminae on the basis of morphological criteria using a light microscope (Zeiss Axiophot) equipped with an image analysis system (a Nikon DS-5Mc camera connected to a personal computer---NIS Elements AR 2.20 Nikon software), and counted as described in Subjects and methods. The graphs show the mean number±s.d. per section. significantly inhibited by the presence of anti-CCL3 (P ¼ 0.001) and anti-IL-11 antibodies (P ¼ 0.04), but not by the anti-immunoglobulin G control (Figures 6b and c) . On the contrary, the presence of MMP-1 had no significant stimulatory effect on OCL formation, and the anti-MMP-1 Ab had no effect on the pro-osteoclastogenic effect of the CM of the cocultures (data not shown).
Osteocyte overexpression of IL-11 in MM patients with bone lesions In order to validate our in vitro observations further, the osteocyte expression of pro-osteoclastogenic cytokines in the bone biopsies of the MM patients was evaluated immunohistochemically. We first confirmed that osteocytes expressed the osteocyte marker sclerostin in vivo (Supplementary Figure S1) , and found that there was no significant difference in expression between the biopsies of the patients with and without bone lesions (data not shown).
We then tested the osteocyte expression of RANKL by means of immunostaining, and found it was negative (Supplementary Figure S2) , thus confirming that the osteocytes did not express this critical osteoclastogenic factor, and the same was true of OPG (data not shown). On the other hand, IL-11 was expressed, and the number of IL-11-positive osteocytes was similar in the three groups (P ¼ NS; Figure 7a ). However, analysis of the MM patients with and without bone lesions showed that the former had significantly more IL-11-positive osteocytes (P ¼ 0.01; Figure 7a ). 
DISCUSSION
The importance of osteocyte death in regulating OCL formation has been highlighted over the recent years: 15 --19 the CM of apoptotic osteocytes turns off their inhibitory effect on OCL activity and triggers local bone resorption in the rat calvaria system, 17 and apoptotic bodies derived from murine osteocytelike MLO-Y4 cells and primary murine osteocytes support osteoclastogenesis and stimulate bone resorption. 18, 19 Interestingly, the role of osteocyte death has also been demonstrated in pathophysiological conditions characterized by a high rate of bone resorption, such as estrogen deficiency, 22 ,23 aging 28 and glucorticoid-induced osteoporosis, 24, 25 and our current findings show that osteocyte death may have a role in MM-induced osteoclastogenesis and bone disease. The potential in vivo role of osteocytes in MM bone disease was investigated by determining osteocyte viability in bone biopsy samples obtained from MM patients and controls. The high rate of osteocyte death in all of the biopsy samples was probably because of the median age of our elderly patients, as previously reported by others. 28 The number of dead osteocytes was higher in our MM patients than in the healthy controls, and similar morphological alterations with a reduced number of osteocyte canaliculi have been found in Figure 5 . Upregulation of pro-osteoclastogenic cytokines in cocultures of HOB-01 and HMCLs. MMP1 and IL11 mRNA levels in HOB-01 preosteocytes were evaluated by means of real-time PCR after 24 h of coculture in the absence or presence of the HMCLs XG-1, JJN3, RPMI-8266 and KMS27, or the lymphoblastoid cell lines IM-9, K562 and 697. The graphs show the median foldchange in mRNA levels observed in two different experiments performed twice (a). IL-11 was detected in the 48-h CM of the XG-1, JJN3, KMS27, IM-9, K562 and 697 cells and HOB-01 preosteocytes incubated in the absence or presence of all of these cell lines placed in a transwell insert. The graphs show the mean IL-11 levels ±s.d. observed in two different experiments performed twice (*Po0.01) (b). MMP-1 was detected in the 48-h CM of JJN3 and XG-1 cells and HOB-01 preosteocytes incubated in the absence or presence of the two HMCLs placed in a transwell insert. The graphs show the mean MMP-1 levels ± s.d. observed in two different experiments performed twice (*P ¼ 0.05; **P ¼ 0.01) (c). CCL3/MIP-1a protein was detected in the CM of JJN3, IM-9, K562 and 697 cells and HOB-01 preosteocytes cocultured with or without JJN3, IM-9, K562 and 697 placed in a transwell insert for 48 h. The graphs show the mean CCL3 levels ± s.d. observed in two different experiments performed twice (*Po0.01) (d). CCL3/MIP1a mRNA levels in JJN3 cells incubated in the absence or presence of HOB-01 preosteocytes in a coculture system using a transwell insert. The graphs show the median foldchange in mRNA levels observed in two different experiments performed twice (e).
patients with bone metastasis, including five with MM. 29 Furthermore, the findings of our analysis of the contents of osteocyte lacunae show for the first time that MM patients with skeletal involvement have significantly fewer viable osteocytes than those without bone lesions. There was no significant difference between MGUS patients and the MM patients as a whole, possibly because of the increased bone resorption that characterizes MGUS, 30 but the MM patients with bone lesions showed a significantly higher rate of osteocyte death. Furthermore, the fact that we did not find a significant difference in osteocyte viability between newly diagnosed and relapsing MM patients confirmed the significant impact of bone status rather than disease status on osteocyte vitality.
Increased osteocyte death has consistently been associated with greater bone fragility and a higher number of bone fractures in vivo, 15, 16, 22, 23, 25 particularly in patients with estrogen deficiency, 22, 23 those receiving glucocorticoids 24, 25 and elderly subjects. 28 Our data support the hypothesis that reduced osteocyte viability may increase bone fragility and the number of fractures in MM patients. This is in line with findings in a mouse model showing that estrogen deficiency, which is characterized by reduced osteocyte viability, 22, 23 may increase MM cell growth and aggressive bone disease. 31, 32 Finally, a TUNEL assay showed that the increased osteocyte death in our MM patients with bone lesions was at least partially due to increased osteocyte apoptosis, as previously reported. As osteocytes arise from OBs, 12,13 the reduced osteocyte viability in MM patients may also be due to the reduced OB formation and inhibition of osteogenic differentiation found in those with osteolytic bone lesions. 1,3,8 --10 It can therefore be hypothesized that the reduced number of OB precursors in the bone microenvironment of MM patients may have a role, although we failed to find any significant relationship between the number of osteoblastic cells and the number of osteocytes in our cohort.
However, regardless of the mechanism involved, the reduced osteocyte viability in MM patients may be important for the recruitment of OCLs because osteocyte death triggers OCL formation in vitro and in vivo. 17, 23, 26 In line with this hypothesis, we found a significant negative correlation between the number of viable osteocytes and the number of OCLs in the bone biopsies of our MM patients.
Our in vivo results were supported by in vitro experimental observations. We first found that MM cells induced osteocyte death and apoptosis in a transwell coculture system, which suggests that they may directly induce osteocyte death. Many of the soluble factors produced by MM cells could be involved in this effect, but we failed to find any significant inhibitory effect of neutralizing anti-TNFa Ab or any significant HMCL production of TNFa (Giuliani et al., personal data) , the main cytokine inducing osteocyte apoptosis. 34 Further studies are needed to clarify this.
Secondly, the CM of the cocultures of HMCLs and the HOB-01 human preosteocyte cell line, which has been shown to express osteocyte markers, 27 stimulated OCL formation. We found that, unlike the murine osteocyte cell line MLO-Y4 18 but like primary human osteocytes, 35 HOB-01 cells do not express the critical osteoclastogenic factor RANKL, and the fact that it was not detected in the CM of the cocultures of HOB-01 and HMCLs suggests that the pro-osteoclastogenic effect was not due to RANKL. In line with this, others have reported that the proosteoclastogenic effect of apoptotic bodies derived from osteocytes is independent of RANKL. 19 Furthermore, our in vitro findings were confirmed by our ex vivo immunohistochemistry data showing the lack of RANKL expression in the bone biopsy osteocytes. We also found that the pro-osteoclastogenic factor CCL3 5 --7 was not expressed by HOB-01 cells, but it was upregulated in the HMCLs cocultured with preosteocytes, and it was involved in the pro-osteoclastogenic effect of the CM, thus suggesting that MM cell CCL3 production is increased in the presence of osteocytes.
We used gene expression profiling analysis to identify the genes in HOB-01 cells that were significantly modulated by HMCLs, and found that MM cells upregulated IL-11 gene expression in cocultured pre-osteocytes, a finding that was confirmed by means of real-time PCR and ELISA. Similarly, we have previously reported that IL-11 is upregulated by both bone marrow stromal and endothelial cells in the presence of MM cells, 36 and other authors have found that MM cells stimulate OB IL-11 production. 37 IL-11 is a cytokine that is known to be critical for OCL formation under physiological conditions, 38, 39 and to be involved in the development of osteolytic bone metastases in breast cancer patients. 40 --42 Interestingly, like other gp130 cytokines, it can induce OCL formation independently of RANKL. 43 We further found that IL-11 increases OCL formation in the presence of RANKL, and that it is at least partially involved in the proosteoclastogenic effect of osteocytes cocultured with HMCLs, as the effect was significantly reduced by anti-IL-11 Ab. The potential role of IL-11 in osteocyte-induced OCL formation was confirmed in vivo by our finding that it was overexpressed in the osteocytes of MM patients with bone lesions. Taken together, these findings support the role of IL-11 in MM-induced osteoclastogenesis.
Microarray analysis showed that MM cells upregulate MMP1 expression in preosteocytes. Although we did not find any direct pro-osteoclastogenic effect of this chemokine in vitro or any inhibitory effect of neutralizing anti-MMP-1 Ab, we cannot exclude the possibility that MMP-1 may have a role in the development of osteolytic bone lesions and bone destruction in MM patients. It has been shown that MMP-1 is a critical factor in the extracellular matrix destruction and osteolysis induced by breast cancer 44, 45 and, in line with our data, it has been reported that MM cells upregulate MMP-1 in bone marrow stromal cells, thus further supporting its potential role in MM-induced bone destruction. 46 On the other hand we found no effect on SOST expression by HOB-01 in coculture with MM cells, as well as no significant difference in sclerostin expression by osteocytes in MM patients as compared with MGUS and healthy controls. However, recent data show that circulating sclerostin levels are higher in MM patients as compared with MGUS and healthy controls with highest levels in those patients with advanced disease including bone fractures. 47 We can suppose that these high sclerostin levels could be derived directly from MM cells rather than from osteocytes because it has been reported that MM cells overexpress sclerostin. 48 Nevertheless, we cannot exclude that apoptotic osteocytes contribute to the increased sclerostin levels in MM patients because it has been reported that pro-apototic factors may induce sclerostin expression by osteocytes and OBs. 49, 50 Overall, our data, in line with several recent evidences, 19,51 --53 support the hypothesis that osteocytic cell death stimulates OCL formation through the upregulation of pro-osteoclastogenic cytokines. Interestingly, in our coculture system, both osteocytic cell death and the upregulation of osteoclastogenic cytokines were not observed with the non-myeloma cell line, suggesting that these effects could be specific for myeloma cells.
Finally, our results showing that osteocyte death occurs in MM patients and correlates with the presence of bone lesions suggest that blocking osteocyte apoptosis may be useful in the management of MM-related bone disease. In this sense, it is important to note that the bisphosphonates, which are widely used to treat MM bone disease, 54, 55 can block osteocyte apoptosis in vitro and in vivo in mouse models. 30, 56 Although the difference in osteocyte viability between MM patients who had or had not previously received bisphosphonates did not reach a statistical significance, the possibility that they may have a positive effect on osteocyte viability cannot be excluded and it should be explored in future studies.
